# MiniMed Stock (MMED): HOLD Call - $319M Owed On The Growth Q1 FY2027

Page: https://stenobird.com/podcast/charged-alpha-stock-encyclopedia-7819792/minimed-stock-mmed-hold-call-319m-owed-on-the-growth-q1-fy2027
Text version: https://stenobird.com/podcast/charged-alpha-stock-encyclopedia-7819792/minimed-stock-mmed-hold-call-319m-owed-on-the-growth-q1-fy2027.md
Podcast: [Charged Alpha Stock Encyclopedia](https://stenobird.com/podcast/charged-alpha-stock-encyclopedia-7819792)
Published: 2026-09-02T04:22:54+00:00
Episode link: https://chargedalpha.podbean.com/e/minimed-stock-mmed-hold-call-319m-owed-on-the-growth-q1-fy2027/
Audio file: https://mcdn.podbean.com/mf/web/s0uh207d3ui12dx5/audio_d.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/charged-alpha-stock-encyclopedia-7819792/episodes/minimed-stock-mmed-hold-call-319m-owed-on-the-growth-q1-fy2027
Duration seconds: 883

## Resource

MiniMed Group (MMED) Q1 FY2027 — MMED closed the reaction session at $22.42, +10.7% - the highest close it has ever had, on 6.07m shares, 5.1x the twenty-day median and 21.7% of the entire public float. MiniMed Flex - the insulin pump behind a U.S. growth acceleration to 13.1% and a +10.7% session - was developed on $324m of funding from Blackstone Life Sciences. For the first two years after U.S. approval and commercial launch, Blackstone earns the greater of a mid-to-high single-digit royalty on net sales or a minimum payment: $157m on Flex and $162m on the MiniMed Fit patch pump. Flex launched in the quarter just reported and Fit was filed with the FDA on the morning of this print, so both clocks are now running. The earnings release does not contain the word Blackstone. THE CALL: HOLD (3/5, MODERATE) — base-case value ~$23.97 vs ~$22.42 today. KEY METRICS: - PERIOD: Q1 of fiscal 2027, ended 31 July 2026, in a year ending 30 April 2027. The SEC submissions metadata says December - it is wrong - NET SALES $843m (+16.6% reported, +15.8% organic) - CGM $431m (+19.9%, now 51% of revenue) - CONSUMABLES $261m (+13.8%) - PUMPS $144m (+21.5%) - U.S. $240m (+13.1%) - INTERNATIONAL $603m (+18.1%) - THIS WAS A 14-WEEK QUARTER: 25 April to 31 July 2026, 98 days against 91. The calendar moved off Medtronic's 52/53-week year to month-end; the company puts the benefit at 4-6% - THE GUIDANCE RAISE IS CLEAN: the June guide said ~10% organic 'includes a 1.0 to 1.5% expected benefit from the extra week'; today's says ~10.5% on identical treatment. 50bp of genuine upgrade - OPERATING INCOME $5m on $843m - a 0.59% margin. Gross profit +$56m, other operating expense -$38m, SG&A -$29m, litigation +$19m, R&D +$10m. Every one of those moved more than the entire result - GAAP EPS $0.…

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/charged-alpha-stock-encyclopedia-7819792/episodes/minimed-stock-mmed-hold-call-319m-owed-on-the-growth-q1-fy2027/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/charged-alpha-stock-encyclopedia-7819792/minimed-stock-mmed-hold-call-319m-owed-on-the-growth-q1-fy2027.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.